Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug;37(4):374-7.
doi: 10.1016/j.canep.2013.03.008. Epub 2013 Apr 13.

Recent changes in endometrial cancer trends among menopausal-age U.S. women

Paige Wartko  1 , Mark E Sherman, Hannah P Yang, Ashley S Felix, Louise A Brinton, Britton Trabert
Affiliations

Recent changes in endometrial cancer trends among menopausal-age U.S. women

Paige Wartko et al. Cancer Epidemiol. 2013 Aug.

Abstract

Background: Changes in endometrial cancer incidence rates after the precipitous decline in menopausal hormone therapy (MHT) use in 2002 have not been evaluated.

Methods: Using data from the Surveillance, Epidemiology, and End Results Program from 1992 to 2009 (SEER 13), we identified 63428 incident endometrial cancer cases among women ages 20-74. We compared annual percent change (APC) in endometrial cancer incidence rates from 1992 to 2002 to rates from 2003 to 2009.

Results: In contrast to the constant endometrial cancer rate pattern observed from 1992 to 2002 (APC 0.0%), rates increased after 2002 in women 50-74 years old (2.5%; PAPC comparison<0.01). Endometrial cancer incidence increased over the entire time period among women ages 20-49 (1992-2002: 1.1%; 2003-2009: 2.1%; PAPC comparison=0.21). Post-2002 increases in incidence among women ages 50-74 were specific to Type I endometrial tumors (1992-2002: -0.6%; 2003-2009: 1.6%; PAPC comparison<0.01).

Discussion: The increase in endometrial cancer incidence rates after 2002 may be related to the widespread decrease in estrogen plus progestin MHT use, which has been reported to lower endometrial cancer risk in overweight and obese women.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Age-adjusted endometrial cancer incidence and annual percent change (APC) among U.S. women, 1992–2009, SEER 13. APC = Annual Percent Change * APC is significantly different from zero (P < 0.05) † APC for 2003–2009 is significantly different from APC for 1992–2002 (P < 0.05)
See this image and copyright information in PMC

References

    1. American Cancer Society Cancer Facts & Figures. 2012
    1. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 2008;108:221–9. - PubMed
    1. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78. - PubMed
    1. Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer. 2012 - PMC - PubMed
    1. Rossouw JE, Anderson GL, Prentice RL, Lacroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–33. - PubMed

Publication types